alpha1-Adrenoceptor subtype selectivity and lower urinary tract symptoms

Area of Science:

• Urology
• Pharmacology

Background:

• Benign prostatic hyperplasia (BPH) is a prevalent condition in aging men, causing urinary flow obstruction and lower urinary tract symptoms (LUTS).
• BPH involves static (prostate size) and dynamic (smooth muscle tone) components.
• Alpha1-adrenoceptors (alpha1ARs) regulate prostate smooth muscle tone, influencing LUTS.

Purpose of the Study:

• To review alpha1AR subtypes and their distribution in lower urinary tract tissues.
• To summarize clinical trial data on the efficacy of alpha1AR blockers for LUTS.
• To discuss benefits, adverse effects, and drug interactions of alpha1AR antagonists.

Main Methods:

• Literature review of published clinical trials on alpha1AR blockers for LUTS.
• Analysis of alpha1AR subtype localization in prostate, bladder, and spinal cord.
• Review of interactions with type 5 phosphodiesterase inhibitors.

Main Results:

• Alpha1AR antagonists effectively relax prostate smooth muscle, reducing urethral resistance and relieving LUTS.
• Different alpha1AR subtypes are found in the prostate, bladder, and spinal cord, influencing therapeutic responses.
• Clinical trials demonstrate the efficacy of alpha1AR blockers in managing LUTS associated with BPH.

Conclusions:

• Alpha1-adrenoceptor antagonists are a primary therapy for LUTS due to BPH.
• Understanding alpha1AR subtypes can guide the rational selection of alpha1AR blocker therapy.
• Knowledge of subtype-specific interactions is crucial for optimizing treatment and managing potential side effects.